Different Potential of G-CSF, GM-CSF, and pIXY in Priming of Myeloid Leukemic Progenitors for Ara-C

[1]  Masahiro Yoshida,et al.  A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments] , 1994 .

[2]  W. Hiddemann,et al.  Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. , 1994, Leukemia.

[3]  T. Palshof,et al.  Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs. , 1993, Leukemia research.

[4]  M. Tanaka.  Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. , 1993, Leukemia research.

[5]  H. Tilly,et al.  Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. , 1993, Leukemia.

[6]  K. Bhalla,et al.  Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells. , 1992, Blood.

[7]  P. Thall,et al.  Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. , 1992, Blood.

[8]  E. McCulloch,et al.  Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity. , 1991, Leukemia.

[9]  M. Andreeff,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. , 1991, Blood.

[10]  F. Herrmann,et al.  Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. , 1990, Experimental hematology.

[11]  E. Estey,et al.  Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. , 1990, Blood.

[12]  S. Cannistra,et al.  Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. , 1989, Leukemia.

[13]  E. McCulloch,et al.  Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. , 1989, Blood.

[14]  P. Porcu,et al.  Interleukin 3 enhances the cytotoxic activity of 1‐β‐d‐arabinofuranosylcytosine (ara‐C) on acute myeloblastic leukaemia (AML) cells , 1988, British journal of haematology.

[15]  T. Chou,et al.  A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. , 1977, The Journal of biological chemistry.

[16]  R. Mertelsmann,et al.  GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). , 1995, Leukemia.

[17]  T. Büchner.  Hematopoietic growth factors in cancer treatment , 1994, Stem cells.

[18]  W. Hiddemann,et al.  The role of GM-CSF in the treatment of acute myeloid leukemia. , 1993, Leukemia & lymphoma.

[19]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.